Skip to main content
SpringerLink
Log in

Timing of re-irradiation in recurrent high-grade gliomas: a single institution study

  • Clinical Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

There is no standard treatment available for recurrent high-grade gliomas. This monoinstitutional retrospective analysis evaluates the differences in overall survival and progression-free survival in patients according to the timing of re-irradiation. Patients suffering from a glioblastoma who received re-irradiation for recurrence were evaluated retrospectively. The median overall survival (OS) and the median progression-free survival were compared with different treatment options and within various time periods. From January 2007 until March 2015, 41 patients suffering from recurrent high-grade gliomas received re-irradiation [median dose of 30.6 Gy (range 20–40 Gy) in median 4 Gy fractions (range 1.8–5 Gy)] in our institution after initial postoperative irradiation or combined radiochemotherapy. The OS in this population was 34 months, and the OS after recurrence (OS-R) was 13 months. After diagnosis of recurrence, patients underwent additional surgical resection after a median of 1.2 months, received a second-line systemic therapy after 2.2 months with or without re-irradiation after 5.7 months. Growth of the tumour was assessed 4.3 months after the start of re-irradiation. The OS after the second surgical resection was 12.2 months, 11.7 months after the start of the second-line systemic therapy, and 6.7 months after the start of re-irradiation. The OS-R was not significantly correlated with the start of re-irradiation after a diagnosis of recurrence or the time period after the previous surgery. At this institution, re-irradiation was performed later compared to other treatment options. However, select patients could benefit from irradiation at an earlier time point. A precise time point should still be evaluated on an individual basis due to the patient’s diverse conditions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. untitled - kid_2015_c70_c72_zns.pdf. 2017 http://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/kid_2015/kid_2015_c70_c72_zns.pdf?__blob=publicationFile. Received 16 Apr 2017

  2. Malzkorn B, Reifenberger G (2016) Practical implications of integrated glioma classification according to the World Health Organization classification of tumors of the central nervous system 2016. Curr Opin Oncol 28:494–501. https://doi.org/10.1097/CCO.0000000000000327

    Article  PubMed  Google Scholar 

  3. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803–820. https://doi.org/10.1007/s00401-016-1545-1

    Article  PubMed  Google Scholar 

  4. AWMF: Detail. 2017 http://www.awmf.org/leitlinien/detail/ll/030-099.html. Received 16 Apr 2017

  5. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996

    Article  PubMed  CAS  Google Scholar 

  6. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466. https://doi.org/10.1016/S1470-2045(09)70025-7

    Article  PubMed  CAS  Google Scholar 

  7. Aktan M, Koc M, Kanyilmaz G (2015) Survival following reirradiation using intensity-modulated radiation therapy with temozolomide in selected patients with recurrent high grade gliomas. Ann Transl Med 3:304–5839. https://doi.org/10.3978/j.issn.2305-5839.2015.11.29

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  8. Combs SE, Bischof M, Welzel T, Hof H, Oertel S, Debus J, Schulz-Ertner D (2008) Radiochemotherapy with temozolomide as re-irradiation using high precision fractionated stereotactic radiotherapy (FSRT) in patients with recurrent gliomas. J Neurooncol 89:205–210. https://doi.org/10.1007/s11060-008-9607-4

    Article  PubMed  Google Scholar 

  9. Minniti G, Armosini V, Salvati M, Lanzetta G, Caporello P, Mei M, Osti MF, Maurizi RE (2011) Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma. J Neurooncol 103:683–691. https://doi.org/10.1007/s11060-010-0446-8

    Article  PubMed  CAS  Google Scholar 

  10. Combs SE, Thilmann C, Edler L, Debus J, Schulz-Ertner D (2005) Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. J Clin Oncol 23:8863–8869

    Article  PubMed  Google Scholar 

  11. Fogh SE, Andrews DW, Glass J, Curran W, Glass C, Champ C, Evans JJ, Hyslop T, Pequignot E, Downes B et al (2010) Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. J Clin Oncol 28:3048–3053. https://doi.org/10.1200/JCO.2009.25.6941

    Article  PubMed  PubMed Central  Google Scholar 

  12. Grosu AL, Weber WA, Franz M, Stark S, Piert M, Thamm R, Gumprecht H, Schwaiger M, Molls M, Nieder C (2005) Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys 63:511–519

    Article  PubMed  CAS  Google Scholar 

  13. Patel M, Siddiqui F, Jin JY, Mikkelsen T, Rosenblum M, Movsas B, Ryu S (2009) Salvage reirradiation for recurrent glioblastoma with radiosurgery: radiographic response and improved survival. J Neurooncol 92:185–191. https://doi.org/10.1007/s11060-008-9752-9

    Article  PubMed  Google Scholar 

  14. Mizumoto M, Okumura T, Ishikawa E, Yamamoto T, Takano S, Matsumura A, Oshiro Y, Ishikawa H, Sakurai H, Tsuboi K (2013) Reirradiation for recurrent malignant brain tumor with radiotherapy or proton beam therapy. Technical considerations based on experience at a single institution. Strahlenther Onkol 189:656–663. https://doi.org/10.1007/s00066-013-0390-6

    Article  PubMed  CAS  Google Scholar 

  15. Fokas E, Wacker U, Gross MW, Henzel M, Encheva E, Engenhart-Cabillic R (2009) Hypofractionated stereotactic reirradiation of recurrent glioblastomas: a beneficial treatment option after high-dose radiotherapy? Strahlenther Onkol 185:235–240. https://doi.org/10.1007/s00066-009-1753-x

    Article  PubMed  Google Scholar 

  16. Ernst-Stecken A, Ganslandt O, Lambrecht U, Sauer R, Grabenbauer G (2007) Survival and quality of life after hypofractionated stereotactic radiotherapy for recurrent malignant glioma. J Neurooncol 81:287–294. https://doi.org/10.1007/s11060-006-9231-0

    Article  PubMed  Google Scholar 

  17. Redmond KJ, Mehta M (2015) Stereotactic radiosurgery for glioblastoma. Cureus 7:e413. https://doi.org/10.7759/cureus.413

    Article  PubMed  PubMed Central  Google Scholar 

  18. Giordano FA, Brehmer S, Abo-Madyan Y, Welzel G, Sperk E, Keller A, Schneider F, Clausen S, Herskind C, Schmiedek P et al (2014) INTRAGO: intraoperative radiotherapy in glioblastoma multiforme-a phase I/II dose escalation study. BMC Cancer 14:992. https://doi.org/10.1186/1471-2407-14-992

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  19. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277–1280

    Article  PubMed  CAS  Google Scholar 

  20. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963–1972. https://doi.org/10.1200/JCO.2009.26.3541

    Article  PubMed  Google Scholar 

  21. Straube C, Elpula G, Gempt J, Gerhardt J, Bette S, Zimmer C, Schmidt-Graf F, Meyer B, Combs SE (2017) Re-irradiation after gross total resection of recurrent glioblastoma. Strahlenther Onkol. https://doi.org/10.1007/s00066-017-1161-6

    Article  PubMed  Google Scholar 

  22. Hudes RS, Corn BW, Werner-Wasik M, Andrews D, Rosenstock J, Thoron L, Downes B, Curran WJ Jr (1999) A phase I dose escalation study of hypofractionated stereotactic radiotherapy as salvage therapy for persistent or recurrent malignant glioma. Int J Radiat Oncol Biol Phys 43:293–298

    Article  PubMed  CAS  Google Scholar 

  23. Yazici G, Cengiz M, Ozyigit G, Eren G, Yildiz F, Akyol F, Gurkaynak M, Zorlu F (2014) Hypofractionated stereotactic reirradiation for recurrent glioblastoma. J Neurooncol 120:117–123. https://doi.org/10.1007/s11060-014-1524-0

    Article  PubMed  Google Scholar 

  24. Navarria P, Ascolese AM, Tomatis S, Reggiori G, Clerici E, Villa E, Maggi G, Bello L, Pessina F, Cozzi L et al (2016) Hypofractionated stereotactic radiation therapy in recurrent high-grade glioma: a new challenge. Cancer Res Treat 48:37–44. https://doi.org/10.4143/crt.2014.259

    Article  PubMed  CAS  Google Scholar 

  25. Balducci M, Diletto B, Chiesa S, D’Agostino GR, Gambacorta MA, Ferro M, Colosimo C, Maira G, Anile C, Valentini V (2014) Low-dose fractionated radiotherapy and concomitant chemotherapy for recurrent or progressive glioblastoma: final report of a pilot study. Strahlenther Onkol 190:370–376. https://doi.org/10.1007/s00066-013-0506-z

    Article  PubMed  CAS  Google Scholar 

  26. Cabrera AR, Cuneo KC, Vredenburgh JJ, Sampson JH, Kirkpatrick JP (2012) Stereotactic radiosurgery and bevacizumab for recurrent glioblastoma multiforme. J Natl Compr Canc Netw 10:695–699

    Article  PubMed  CAS  Google Scholar 

  27. Flieger M, Ganswindt U, Schwarz SB, Kreth FW, Tonn JC, la Fougere C, Ertl L, Linn J, Herrlinger U, Belka C et al (2014) Re-irradiation and bevacizumab in recurrent high-grade glioma: an effective treatment option. J Neurooncol 117:337–345. https://doi.org/10.1007/s11060-014-1394-5

    Article  PubMed  CAS  Google Scholar 

  28. Gutin PH, Iwamoto FM, Beal K, Mohile NA, Karimi S, Hou BL, Lymberis S, Yamada Y, Chang J, Abrey LE (2009) Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 75:156–163. https://doi.org/10.1016/j.ijrobp.2008.10.043

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  29. Chinot OL, de La Motte Rouge T, Moore N, Zeaiter A, Das A, Phillips H, Modrusan Z, Cloughesy T (2011) AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Adv Ther 28:334–340. https://doi.org/10.1007/s12325-011-0007-3

    Article  PubMed  CAS  Google Scholar 

  30. Greenspoon JN, Sharieff W, Hirte H, Overholt A, Devillers R, Gunnarsson T, Whitton A (2014) Fractionated stereotactic radiosurgery with concurrent temozolomide chemotherapy for locally recurrent glioblastoma multiforme: a prospective cohort study. Onco Targets Ther 7:485–490. https://doi.org/10.2147/OTT.S60358

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  31. Kong DS, Lee JI, Park K, Kim JH, Lim DH, Nam DH (2008) Efficacy of stereotactic radiosurgery as a salvage treatment for recurrent malignant gliomas. Cancer 112:2046–2051. https://doi.org/10.1002/cncr.23402

    Article  PubMed  Google Scholar 

  32. Niyazi M, Karin I, Sohn M, Nachbichler SB, Lang P, Belka C, Ganswindt U (2013) Analysis of equivalent uniform dose (EUD) and conventional radiation treatment parameters after primary and re-irradiation of malignant glioma. Radiat Oncol 8:287–717. https://doi.org/10.1186/1748-717X-8-287

    Article  PubMed  PubMed Central  Google Scholar 

  33. Swanson KD, Lok E, Wong ET (2016) An overview of alternating electric fields therapy (NovoTTF therapy) for the treatment of malignant glioma. Curr Neurol Neurosci Rep. https://doi.org/10.1007/s11910-015-0606-5

    Article  PubMed  PubMed Central  Google Scholar 

  34. Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V, Kirson ED, Taillibert S, Liebermann F, Dbalý V et al (2012) NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer 48:2192–2202

    Article  PubMed  Google Scholar 

  35. Chamberlain MC, Kim BT (2017) Nivolumab for patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series. J Neurooncol. https://doi.org/10.1007/s11060-017-2466-0

    Article  PubMed  Google Scholar 

  36. Vordermark D, Kolbl O, Ruprecht K, Vince GH, Bratengeier K, Flentje M (2005) Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma. BMC Cancer 5:55

    Article  PubMed  PubMed Central  Google Scholar 

  37. Ciammella P, Podgornii A, Galeandro M, D’Abbiero N, Pisanello A, Botti A, Cagni E, Iori M, Iotti C (2013) Hypofractionated stereotactic radiation therapy for recurrent glioblastoma: single institutional experience. Radiat Oncol 8:222–717. https://doi.org/10.1186/1748-717X-8-222

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Strahlentherapie und spezielle Onkologie, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Germany

    A. Zemlin, B. Märtens, R. Merten & D. Steinmann

  2. Klinik für Neurologie und klinische Neurophysiologie, DIAKOVERE Henriettenstift gGmbH, Marienstr. 72-90, 30171, Hannover, Germany

    B. Wiese

Authors
  1. A. Zemlin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. Märtens
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B. Wiese
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. Merten
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D. Steinmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Zemlin.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This study was approved by the ethics committee of MHH.

Research involving human participants and/or animals

This article does not contain any studies with human participants or animals performed by any of the authors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zemlin, A., Märtens, B., Wiese, B. et al. Timing of re-irradiation in recurrent high-grade gliomas: a single institution study. J Neurooncol 138, 571–579 (2018). https://doi.org/10.1007/s11060-018-2824-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-018-2824-6

Keywords

Search

Navigation